SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* Crouse Steven C. (Last) (First) (Middle) 614 MCKINLEY PLACE NE (Street) MINNEAPOLIS MINNESOTA 55413 (City) (State) (Zip) UNITED STATES (Country)	2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [ TECH ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) President - Diag & Spatial Bi
	2a. Foreign Trading Symbol
	3. Date of Earliest Transaction (Month/Day/Year) 08/17/2026	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
	4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								10,237	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$97.13							(1)	04/01/2028	Common Stock	3,856		3,856	D
Stock Option (right to buy)	$120.46							(1)	08/06/2028	Common Stock	19,032		19,032	D
Stock Option (right to buy)	$94.52							(1)	08/15/2029	Common Stock	24,560		24,560	D
Stock Option (right to buy)	$84.61							(2)	08/15/2030	Common Stock	12,649		12,649	D
Stock Option (right to buy)	$73.46							(3)	05/01/2031	Common Stock	7,327		7,327	D
Stock Option (right to buy)	$74.91							(4)	08/15/2034	Common Stock	17,133		17,133	D
Stock Option (right to buy)	$48.61							(5)	06/02/2035	Common Stock	5,434		5,434	D
Stock Option (right to buy)	$53.6							(6)	08/15/2035	Common Stock	19,151		19,151	D
Stock Option (right to buy)	$57.82							(7)	03/02/2036	Common Stock	1,911		1,911	D
Performance Restricted Stock Units	(8)							(9)	(9)	Common Stock	2,387		2,387	D
Restricted Stock Units	(8)							(10)	(10)	Common Stock	794		794	D
Restricted Stock Units	(8)							(11)	(11)	Common Stock	1,200		1,200	D
Restricted Stock Units	(8)							(12)	(12)	Common Stock	1,869		1,869	D
Restricted Stock Units	(8)							(13)	(13)	Common Stock	4,353		4,353	D
Restricted Stock Units	(8)							(14)	(14)	Common Stock	735		735	D
Restricted Stock Units	(8)	08/17/2026		A		8,702		(15)	(15)	Common Stock	8,702	$0	8,702	D
Restricted Stock Units	(8)	08/17/2026		A		14,140		(16)	(16)	Common Stock	14,140	$0	14,140	D

Explanation of Responses:

1. 100% vested.

2. Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025.

3. Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027.

4. Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026.

5. Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029.

6. Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028.

7. Options to purchase 478 shares vest on each of 3/2/2027, 3/2/2028 and 3/2/2030; and options to purchase 477 shares vest on 3/2/2029.

8. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

9. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

10. 794 restricted stock units vest on 5/1/2027.

11. 600 restricted stock units vest on each of 6/2/2027 and 6/2/2028.

12. 1,869 restricted stock units vest on 8/15/2027.

13. 2,177 restricted stock units vest on 8/15/2027, and 2,176 restricted stock units vest on 8/15/2028.

14. 245 restricted stock units vest on each of 3/2/2027, 3/2/2028 and 3/2/2029.

15. 2,901 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 2,900 restricted stock units vest on 8/17/2029.

16. 14,140 restricted stock units vest on 8/17/2029.

	/s/ Andrew Nick as Attorney-in-Fact for Steven C. Crouse pursuant to Power of Attorney previously filed.	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)